{"title": "PPT - Hepatitis A Hepatitis B Hepatitis no A no B: C, D, E,\u2026.? Com\u00fan: PowerPoint Presentation - ID:5688737", "author": "Damisi", "url": "https://www.slideserve.com/damisi/hepatitis-a-hepatitis-b-hepatitis-no-a-no-b-c-d-e-com-n", "hostname": "slideserve.com", "description": "HEPATITIS V\u00cdRICAS: EVOLUCI\u00d3N HIST\u00d3RICA. Hepatitis A Hepatitis B Hepatitis no A no B: C, D, E,\u2026.? Com\u00fan:. Afectan al h\u00edgado Ictericia Enzimas hep\u00e1ticas elevadas. CLASIFICACI\u00d3N SEG\u00daN MECANISMO DE TRANSMISI\u00d3N. Dozens of Oklahoma Dentist's Patients Test Positive for Hepatitis.", "sitename": "SlideServe", "date": "2014-10-21", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "330 likes | 756 Views\nHEPATITIS V\u00cdRICAS: EVOLUCI\u00d3N HIST\u00d3RICA. Hepatitis A Hepatitis B Hepatitis no A no B: C, D, E,\u2026.? Com\u00fan:. Afectan al h\u00edgado Ictericia Enzimas hep\u00e1ticas elevadas. CLASIFICACI\u00d3N SEG\u00daN MECANISMO DE TRANSMISI\u00d3N. Dozens of Oklahoma Dentist's Patients Test Positive for Hepatitis.\nE N D\n[HEPATITIS V\u00cdRICAS: EVOLUCI\u00d3N HIST\u00d3RICA](https://image3.slideserve.com/5688737/slide1-l.jpg) \u2022 Hepatitis A \u2022 Hepatitis B \u2022 Hepatitis no A no B: C, D, E,\u2026.? \u2022 Com\u00fan: Afectan al h\u00edgado Ictericia Enzimas hep\u00e1ticas elevadas [Dozens of Oklahoma Dentist's Patients Test Positive for](https://image3.slideserve.com/5688737/dozens-of-oklahoma-dentist-s-patients-test-positive-for-hepatitis-l.jpg) Hepatitis Reuters HealthInformationApr 19, 2013 OKLAHOMA CITY (Reuters) Apr 18 - Bloodtestsconductedonpatientstreated at an Oklahoma oral surgerypracticethat has beenclosedoverhealthconcerns show that: \u2022 57 have hepatitis C, \u2022 threehave hepatitis B and \u2022 as many as threehave HIV, [Dozens of Oklahoma Dentist's Patients Test Positive for](https://image3.slideserve.com/5688737/dozens-of-oklahoma-dentist-s-patients-test-positive-for-hepatitis1-l.jpg) Hepatitis Reuters HealthInformationApr 19, 2013 Healthofficials so farhavescreened3,122patientswhounderwent oral surgeryprocedures at clinicsoperatedbyDr Scott Harrington, a Tulsa oral surgeonwhoisaccused of usingimpropersterilizationtechniques. [Las Epidemias Silenciosas](https://image3.slideserve.com/5688737/las-epidemias-silenciosas-l.jpg) \u2022 Infecc. cr\u00f3nica porVHB\u2026\u2026\u2026..240 millones. \u2022 Infecc. cr\u00f3nica porVHC\u2026\u2026\u2026\u2026.170 millones. \u2022 Infecci\u00f3n porVIH\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202634 millones. [VIRUS DE LA HEPATITIS B: CARACTER\u00cdSTICAS](https://image3.slideserve.com/5688737/slide6-l.jpg) \u2022 Virus de ADN parcialmente bicatenario envuelto \u2022 Familia Hepadnaviridae \u2022 Distintos tipos antig\u00e9nicos con comportamiento similar \u2022 No cultivable [Ag HBc \u00f3 core](https://image3.slideserve.com/5688737/slide7-l.jpg) ADN Ag HBs \u00f3 Australia ADN polimerasa VIRUS DE LA HEPATITIS B: ESTRUCTURA [VIRUS DE LA HEPATITIS B: ](https://image3.slideserve.com/5688737/slide8-l.jpg) REPLICACI\u00d3N VIRAL [HEPATITIS B: CL\u00cdNICA](https://image3.slideserve.com/5688737/slide11-l.jpg) \u2022 Periodo de incubaci\u00f3n m\u00e1s largo (7-160 d\u00edas) \u2022 Inicio m\u00e1s lento \u2022 Todas las edades \u2022 Afectaci\u00f3n hep\u00e1tica moderada \u2022 Existen casos cr\u00f3nicos \u2022 Adultos: 10 % \u2022 Neonatos: 90 % [HEPATITIS B: DIAGN\u00d3STICO](https://image3.slideserve.com/5688737/slide13-l.jpg) \u2022 Detecci\u00f3n de la ADN polimerasa \u2022 Detecci\u00f3n ADN viral: hibridaci\u00f3n o PCR \u2022 Detecci\u00f3n de Ag y Ac por t\u00e9cnicas de ELISA: \u2022 Anti-HBc \u2022 HBsAg/Anti-HBs \u2022 HBeAg/Anti-HBe \u2022 Patrones serol\u00f3gicos \u201cimposibles\u201d en infecciones por cepas mutantes [HEPATITIS B: EPIDEMIOLOG\u00cdA](https://image3.slideserve.com/5688737/slide16-l.jpg) \u2022 Distribuci\u00f3n mundial (240 millones de infectados cr\u00f3nicamente) \u2022 Endemicidad variable (depende del porcentaje de portadores cr\u00f3nicos asintom\u00e1ticos [0,3-8%]) \u2022 Reservorio: Hombre infectado \u2022 Transmisi\u00f3n: \u2022 Parenteral (0.0001 ml de sangre) \u2022 Sexual \u2022 Vertical o materno-fetal [Hepatitis y drogadicci\u00f3n i.v. (AVP)](https://image3.slideserve.com/5688737/hepatitis-y-drogadicci-n-i-v-avp-l.jpg) \u2022 16 millones de AVP en 148 pa\u00edses. \u2022 1.200.00 AVP infectados por VHB. \u2022 10.000.000 AVP infectados por VHC. (60-80% de los AVP) [HEPATITIS B: PROFILAXIS](https://image3.slideserve.com/5688737/slide19-l.jpg) \u2022 Vacunas (\u00a1\u00a1\u00a1Ojo: aparici\u00f3n de cepas con HBsAg mutado con baja afinidad por los Anti-HBs inducidos por la vacuna!!!) \u2022 Medidas de \u00edndole general \u2022 Control de donaciones de sangre, hemoderivados y \u00f3rganos \u2022 Uso de material desechable \u2022 M\u00e9todos de barrera \u2022 Inmunizaci\u00f3n pasiva [VIRUS DE LA HEPATITIS D (DELTA)](https://image3.slideserve.com/5688737/slide20-l.jpg) \u2022 Virus de ARN monocatenario peque\u00f1o y defectivo (necesita al Ag HBs para infectar y replicarse) \u2022 15 millones de infectados en el mundo \u2022 40% de hepatitis fulminantes [VIRUS DE LA HEPATITIS D (DELTA)](https://image3.slideserve.com/5688737/slide21-l.jpg) \u2022 Formas de presentaci\u00f3n: \u2022 Coinfecci\u00f3n VHB + VHD: aumenta la gravedad de VHB \u2022 Sobreinfecci\u00f3n en pacientes con HB cr\u00f3nica: progresi\u00f3n m\u00e1s r\u00e1pida y grave \u2022 Diagn\u00f3stico serol\u00f3gico (Ig espec\u00edficas) \u2022 Epidemiolog\u00eda y profilaxis la de la HB [VIRUS DE LA HEPATITIS C](https://image3.slideserve.com/5688737/slide22-l.jpg) \u2022 Virus de ARN de polaridad positiva \u2022 Familia Flaviviridae \u2022 No cultivable \u2022 Diferentes genotipos con distinto comportamiento \u2022 La infecci\u00f3n suele ser asintom\u00e1tica o leve \u2022 Hasta el 85% de los casos cronifican [POR QU\u00c9 EL VHC TIENDE A LA CRONICIDAD](https://image3.slideserve.com/5688737/slide24-l.jpg) \u2022 El virus tiene frecuentes errores en la replicaci\u00f3n \u2192 frecuente aparici\u00f3n de mutantes \u2022 La respuesta inmune resulta ineficaz frente a los mutantes \u2022 El virus se asocia a la c\u00e9lula e inhibe la apoptosis \u2022 Reacci\u00f3n inmunopatol\u00f3gica [VIRUS DE LA HEPATITIS C](https://image3.slideserve.com/5688737/slide25-l.jpg) \u2022 Diagn\u00f3stico: \u2022 Dif\u00edcil en formas agudas \u2022 Serolog\u00eda en formas cr\u00f3nicas \u2022 Detecci\u00f3n de ARN viral \u2022 Transmisi\u00f3n: Parenteral (menos importantes las v\u00edas sexual, salvo si se padece otra ETS, y vertical, salvo en coinfectadas por VIH) \u2022 Profilaxis: \u2022 Control de transfusiones y transplantes \u2022 No hay vacunas [VIREMIA EN HEPATITIS C](https://image3.slideserve.com/5688737/slide26-l.jpg) \u2022 INFECCI\u00d3N AGUDA: 4-6 MESES \u2022 INFECCI\u00d3N CR\u00d3NICA: > 10 A\u00d1OS [\u00bfQu\u00e9 hacer para evitar el contagio ocupacional de](https://image3.slideserve.com/5688737/slide29-l.jpg) hepatitis? \u2022 Vacunaci\u00f3n frente a VHB obligatoria \u2022 Adopci\u00f3n rutinaria de precauciones universales: \u2022 Lavado de manos (agua, jab\u00f3n, desinfectante) \u2022 Vestuario protector adecuado (guantes, mascarilla,\u2026) \u2022 Uso correcto de material desechable y reutilizable \u2022 Medidas adicionales postexposici\u00f3n: \u2022 Heridas o zonas de piel en contacto con sangre o fluidos corporales: Lavar con agua y jab\u00f3n \u2022 Contacto a traves de mucosas: Lavar con abundante agua o suero fisiol\u00f3gico [\u00bfQu\u00e9 hacer para evitar el contagio ocupacional de](https://image3.slideserve.com/5688737/slide30-l.jpg) hepatitis? \u2022 Medidas espec\u00edficas: \u2022 Evaluar riesgo de Hepatitis B: \u2022 Paciente como fuente de infecci\u00f3n: Saber si es HBsAg +/-. Si se desconoce se proceder\u00e1 como si fuese + \u2022 Persona accidentada: saber si est\u00e1 inmunizada o no frente a VHB: \u2022 Si tiene AntiHBs no hay que hacer nada. \u2022 Si no tiene AntiHBs:Inmunoglobulina espec\u00edfica VHB e iniciar vacunaci\u00f3n [\u00bfQu\u00e9 hacer para evitar el contagio ocupacional de](https://image3.slideserve.com/5688737/slide31-l.jpg) hepatitis? \u2022 Medidas espec\u00edficas: \u2022 Evaluar riesgo de Hepatitis C: \u2022 Paciente como fuente de infecci\u00f3n: Presencia o no de Ac frente VHC \u2022 Persona accidentada: Estudiar situaci\u00f3n basal frente VHC y enzimas hep\u00e1ticos. Seguimiento peri\u00f3dico. Tratamiento precoz de hepatitis si aparece", "language": null, "image": "https://cdn3.slideserve.com/5688737/slide1-n.jpg", "pagetype": "article", "links": ["\\", "#", "/presentations", "/presentations", "/topics", "/updates", "/featured", "/powerpoint-templates", "/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/article-stories", "/online-survey", "/online-quiz", "/lead-generation", "/create?type=ebook&utm_source=slideserve&utm_medium=website&utm_campaign=ebook+creator", "https://www.slideserve.com/create?utm_source=slideserve&utm_medium=website&utm_campaign=presentation+creator", "/pro", "/upload", "/damisi", "https://image3.slideserve.com/5688737/slide1-l.jpg", "https://image3.slideserve.com/5688737/slide2-l.jpg", "https://image3.slideserve.com/5688737/dozens-of-oklahoma-dentist-s-patients-test-positive-for-hepatitis-l.jpg", "https://image3.slideserve.com/5688737/dozens-of-oklahoma-dentist-s-patients-test-positive-for-hepatitis1-l.jpg", "https://image3.slideserve.com/5688737/las-epidemias-silenciosas-l.jpg", "https://image3.slideserve.com/5688737/slide6-l.jpg", "https://image3.slideserve.com/5688737/slide7-l.jpg", "https://image3.slideserve.com/5688737/slide8-l.jpg", "https://image3.slideserve.com/5688737/slide9-l.jpg", "https://image3.slideserve.com/5688737/slide10-l.jpg", "https://image3.slideserve.com/5688737/slide11-l.jpg", "https://image3.slideserve.com/5688737/slide12-l.jpg", "https://image3.slideserve.com/5688737/slide13-l.jpg", "https://image3.slideserve.com/5688737/slide14-l.jpg", "https://image3.slideserve.com/5688737/slide15-l.jpg", "https://image3.slideserve.com/5688737/slide16-l.jpg", "https://image3.slideserve.com/5688737/hepatitis-y-drogadicci-n-i-v-avp-l.jpg", "https://image3.slideserve.com/5688737/slide18-l.jpg", "https://image3.slideserve.com/5688737/slide19-l.jpg", "https://image3.slideserve.com/5688737/slide20-l.jpg", "https://image3.slideserve.com/5688737/slide21-l.jpg", "https://image3.slideserve.com/5688737/slide22-l.jpg", "https://image3.slideserve.com/5688737/slide23-l.jpg", "https://image3.slideserve.com/5688737/slide24-l.jpg", "https://image3.slideserve.com/5688737/slide25-l.jpg", "https://image3.slideserve.com/5688737/slide26-l.jpg", "https://image3.slideserve.com/5688737/slide27-l.jpg", "https://image3.slideserve.com/5688737/slide28-l.jpg", "https://image3.slideserve.com/5688737/slide29-l.jpg", "https://image3.slideserve.com/5688737/slide30-l.jpg", "https://image3.slideserve.com/5688737/slide31-l.jpg", "/bernad/acute-hepatitis-c", "/fiona/algoritmo-para-el-diagn-stico-de-las-hepatitis-virales", "/enrique/affordability-of-hiv", "/maalik/21th-vhpb-meeting-on-prevention-of-viral-hepatitis-in-italy-lessons-learnt-and-the-way-forward-catania-7-8-novembe", "/bliss/a-ch-19-section-2-h-ch-25", "/triage/adnan-iqbal-12-10005", "/armani/actualizaci-n-en-hepatitis-b-manejo-de-la-resistencia-de-drogas-antivirales", "/norah/acute-viral-hepatitis", "/lilike/5-th-paris-hepatitis-congress-workshop-30-1-2012-managing-complications-of-daas-case-1", "/geneva/acute-viral-hepatitis", "/tierra/21-reuni-n-anual-de-unidades-centinela-para-hepatitis-virales-15-y-16-de-octubre-2012", "/kyrie/adefovir-dipivoxil-10-mg-for-the-treatment-of-chronic-hepatitis-b", "/cheng/194-mir-01-cu-l-de-las-siguientes-opciones-no-es-cierta-sobre-la-infecci-n-vih", "/elsie/25-hepatitis-virus", "/orly/about-this-presentation", "/maxim/a-training-guide-for-community-care-health-and-social-service-providers", "/villette-leclerc/aids-cases-with-tb-florida-2012-powerpoint-ppt-presentation", "/athena-alexander/aids-cases-with-tb-florida-2011-powerpoint-ppt-presentation", "/stone-graham/acute-hepatitis-c-virus-infection-epidemiology-clinical-features-and-diagnosis", "/hayes-fuentes/abstract", "/Shubhangi/aarkstore-hepatitis-a-pipeline-review-h1-2014", "//www.slideserve.com", "//fr.slideserve.com", "/about", "/privacy", "/dmca", "https://blog.slideserve.com", "/contact", "https://www.facebook.com/SlideServe", "https://twitter.com/slideserve", "https://www.youtube.com/user/SlideServe", "https://www.pinterest.com/slideserve/"]}